文献速递乳腺乳腺X线

对比增强乳腺X线在筛查召回女性中的诊断效能:≥3年随访乳腺分析

CEM in women prospectively assessed for screening recalls: Per-breast diagnostic performance with 3-year or longer follow-up.
PubMed 文献 · Eur J Radiol · 2026-01-01

对意大利两家中心207例筛查召回女性前瞻性纳入研究,行对比增强乳腺X线检查与标准评估,以组织病理和/或≥3年随访为参考标准。乳腺水平分析显示CEM敏感度约96%、特异度95%、阴性预测值99%,提示其在筛查召回评估中具有良好的排除恶性能力。

要点

  • CEM在筛查召回女性中乳腺水平阴性预测值达99.0%,适合用于避免不必要的活检
  • 乳腺水平敏感度96.1%、特异度94.9%,兼顾检出与排除能力
  • 随访期出现3例间隔癌,均无淋巴结转移,提示低漏诊风险但需关注随访

核心结论

  • 在筛查召回女性中,以≥3年随访为标准,CEM乳腺水平敏感度约96%、特异度95%、阴性预测值99%

研究设计与样本

  • 前瞻性研究,纳入意大利两家中心207例筛查钼靶召回女性,共414个乳腺
  • 所有女性均接受CEM及标准评估,包括加拍体位、断层合成和/或超声
  • 标准评估与CEM独立判读,建议活检或返回下一轮筛查
  • 参考标准为组织病理和/或≥3年随访,393个乳腺有完整数据纳入分析

关键影像表现/征象

  • 393个乳腺中316个(80.4%)在初始活检或随访中为阴性
  • 393个乳腺中74个(18.8%)在初始活检确诊恶性
  • 随访期间发现3例间隔癌(0.8%),两例在1年随访、一例在3年随访时发现
  • 间隔癌包括1例导管原位癌,2例淋巴结阴性浸润性癌(一例5毫米混合型非特殊类型/小叶癌,一例6毫米黏液癌)

诊断标准与关键数值

  • 以393个乳腺分析,CEM乳腺水平敏感度96.1%(74/77,95%CI 89.3-98.8%)
  • CEM乳腺水平特异度94.9%(300/316,95%CI 92.0-96.9%)
  • CEM乳腺水平准确度95.2%(374/393,95%CI 92.6-97.1%)
  • CEM乳腺水平阳性预测值82.2%(74/90,95%CI 73.2-88.8%)
  • CEM乳腺水平阴性预测值99.0%(300/303,95%CI 97.2-99.7%)

临床应用与阅片要点

  • CEM低能图与重组图联合判读,对筛查召回乳腺具有很高的排除恶性能力
  • 当CEM判读为阴性时,可较有信心地建议返回下一轮常规筛查
  • 判读时应警惕黏液癌等特殊类型,本研究中一例6毫米黏液癌在3年随访才被发现

局限性

  • 间隔癌仅3例,数量少,无法对漏诊模式进行亚组分析
  • 研究局限于意大利两家中心,结果的外部推广需谨慎

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the performance of contrast-enhanced mammography (CEM) for the assessment of screening recalls at ≥ 3-year follow-up.

MATERIALS AND METHODS: Women recalled after screening mammography at two Italian centers were prospectively enrolled to undergo CEM alongside standard assessment (SA) through additional views, tomosynthesis, and/or ultrasound. SA and CEM were independently evaluated, recommending biopsy or referral to a subsequent screening round. Per-breast diagnostic performance of CEM (low-energy plus recombined images) was calculated by taking histopathology and/or ≥ 3-year follow-up as the reference standard.

RESULTS: Of the original 414 breasts (from 207 women), 393 (from 198 women) had available biopsy or follow-up data for the purposes of this analysis, being negative either at the original biopsy or at follow-up (316/393, 80.4%), or having a malignant finding at the original biopsy (74/393, 18.8%), or an interval cancer during follow-up (3/393, 0.8%, two at 1-year, one at 3-year). These interval cancers were 1 DCIS, two node-negative invasive (one 5-mm mixed no special type/lobular; one 6-mm mucinous). Per-breast analysis of the 393 breasts yielded a 96.1% sensitivity (74/77, 95% confidence interval 89.3-98.8%), 94.9% specificity (300/316, 92.0-96.9%), 95.2% accuracy (374/393, 92.6-97.1%), 82.2% positive predictive value (74/90, 73.2-88.8%), 99.0% negative predictive value (300/303, 97.2-99.7%).

CONCLUSIONS: In a cohort of women undergoing screening recall with CEM, when considering ≥ 3-year follow-up, per-breast sensitivity was about 96 %, specificity 95 %, negative predictive value 99 %.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Marziali, Cozzi, Magni, et al. CEM in women prospectively assessed for screening recalls: Per-breast diagnostic performance with 3-year or longer follow-up. Eur J Radiol. 2026. PMID: 41499915. doi:10.1016/j.ejrad.2025.112652

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。